Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The hallmarks of cancer.Cell. 2000; 100: 57-70
- Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.Oncogene. 1989; 4: 1363-1374
- Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.J Invest Dermatol. 2001; 117: 1483-1489
- Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.Cancer Res. 2003; 63: 3955-3957
- Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.Clin Cancer Res. 2002; 8: 3468-3474
- BRAF and RAS mutations in human lung cancer and melanoma.Cancer Res. 2002; 62: 6997-7000
- BRAF and NRAS mutations in melanoma and melanocytic nevi.Melanoma Res. 2006; 16: 267-273
- Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.J Cutan Pathol. 2005; 32: 334-339
- NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.Clin Cancer Res. 2003; 9: 6483-6488
- BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.Am J Dermatopathol. 2003; 25: 365-370
- The role of B-RAF in melanoma.Cancer Metastasis Rev. 2005; 24: 165-183
- New insight into BRAF mutations in cancer.Curr Opin Genet Dev. 2007; 17: 31-39
- Absence of BRAF gene mutation in non-melanoma skin tumors.Cell Cycle. 2006; 5: 968-970
- Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.J Invest Dermatol. 2007; 127: 179-182
- Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi.Br J Dermatol. 1994; 131: 72-77
- BRAF mutations are common somatic events in melanocytic nevi.J Invest Dermatol. 2004; 122: 342-348
- High frequency of BRAF mutations in nevi.Nat Genet. 2003; 33: 19-20
- High BRAF mutation frequency does not characterize all melanocytic tumor types.Int J Cancer. 2004; 111: 705-710
- The precursors of malignant melanoma.Recent Results Cancer Res. 2002; 160: 75-84
- Do all melanomas come from “moles”? A study of the histological association between melanocytic naevi and melanoma.Australas J Dermatol. 1990; 31: 77-80
- Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.Am J Pathol. 2004; 164: 1783-1787
- Distinct sets of genetic alterations in melanoma.N Engl J Med. 2005; 353: 2135-2147
- Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.Clin Cancer Res. 2004; 10: 3444-3447
- Absence of BRAF mutations in UV-protected mucosal melanomas.J Med Genet. 2004; 41: 270-272
- BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.J Clin Pathol. 2005; 58: 640-644
- Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.J Invest Dermatol. 2004; 122: 337-341
- Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.Cancer Res. 2000; 60: 1800-1804
- PTEN signaling pathways in melanoma.Oncogene. 2003; 22: 3113-3122
- BRAF alterations are associated with complex mutational profiles in malignant melanoma.Oncogene. 2004; 23: 5968-5977
- Malignant melanoma.Arch Pathol Lab Med. 2001; 125: 1295-1306
- Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.Hum Pathol. 2004; 35: 25-33
- p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.Int J Cancer. 1997; 74: 26-30
- Germline p16 mutations in familial melanoma.Nat Genet. 1994; 8: 15-21
- Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.Nat Genet. 1994; 8: 23-26
- Melanoma.N Engl J Med. 2006; 355: 51-65
- Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.Cancer Res. 1995; 55: 2713-2718
- An analysis of p16 protein expression in sporadic malignant melanoma.Melanoma Res. 1998; 8: 267-272
- Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.Int J Cancer. 1997; 74: 255-259
- Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.Clin Cancer Res. 2000; 6: 1845-1853
- Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.J Invest Dermatol. 1998; 110: 932-938
- Cyclin D1 is a candidate oncogene in cutaneous melanoma.Cancer Res. 2002; 62: 3200-3206
- BRAFE600-associated senescence-like cell cycle arrest of human naevi.Nature. 2005; 436: 720-724
- Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.Cell. 1997; 88: 593-602
- Cellular senescence in naevi and immortalisation in melanoma: a role for p16?.Br J Cancer. 2006; 95: 496-505
- Human melanocyte senescence and melanoma susceptibility genes.Oncogene. 2003; 22: 3063-3069
- Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside.J Invest Dermatol. 2008; 128: 2575-2595
- The Rb family connects with the Tp53 family in skin carcinogenesis.Mol Carcinog. 2007; 46: 618-623
- Mutations of the BRAF gene in human cancer.Nature. 2002; 417: 949-954
- BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.Curr Biol. 2005; 15: 249-254
- Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.Nat Genet. 2005; 37: 745-749
- Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol. 2001; 19: 3635-3648
- An evidence-based staging system for cutaneous melanoma.CA Cancer J Clin. 2004; 54 ([quiz: 182–4]): 131-149
- Genome-wide profiling of gene amplification and deletion in cancer.Hum Cell. 2000; 13: 135-141
- Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.Cell. 2006; 125: 1269-1281
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.Nature. 2005; 436: 117-122
- MITF: master regulator of melanocyte development and melanoma oncogene.Trends Mol Med. 2006; 12: 406-414
- The melanocytic proliferations.Wiley-Blackwell, London2001
- Medicolegal issues in surgical pathology.in: Weidner N. Modern surgical pathology. vol. 1. Saunders, 1st edition. Philadelphia2003: 139-149
- Error in surgical pathology.Am J Surg Pathol. 2004; 28: 1092-1095
- Tutorial on melanocytic lesions.Am J Dermatopathol. 2001; 23: 237-241
- Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists.Hum Pathol. 1996; 27: 528-531
- Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome.Hum Pathol. 1999; 30: 513-520
- Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.Am J Pathol. 2000; 157: 967-972
- Lack of BRAF mutations in Spitz nevi.J Invest Dermatol. 2004; 122: 1325-1326
- Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.Br J Dermatol. 2007; 156: 1287-1294
- Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.Am J Surg Pathol. 2005; 29: 1145-1151
- Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.Cancer Res. 1998; 58: 2170-2175
- Classifying melanocytic tumors based on DNA copy number changes.Am J Pathol. 2003; 163: 1765-1770
- Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma.Am J Surg Pathol. 2009; 33: 1146-1156
- Genomic analysis of metastasis reveals an essential role for RhoC.Nature. 2000; 406: 532-535
- Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.Cancer Cell. 2002; 1: 279-288
- Molecular classification of cutaneous malignant melanoma by gene expression profiling.Nature. 2000; 406: 536-540
- Understanding spitzoid tumours: new insights from molecular pathology.Br J Dermatol. 2008; 158: 4-14
- Somatic activation of KIT in distinct subtypes of melanoma.J Clin Oncol. 2006; 24: 4340-4346
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.Nature. 2009; 457: 599-602
- Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.Am J Surg Pathol. 2007; 31: 1764-1775
Article info
Footnotes
A version of this article was previously published in Surgical Pathology Clinics 2:3.
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
